| Identification | Back Directory | [Name]
Lexacalcitol | [CAS]
131875-08-6 | [Synonyms]
KH 106
KH 1060
Lexacalcitol
Lenosacalcitol
Lexacalcideferol
(1S*,3R*,5Z),7aalpha))-(5Z,7E,20R)-20-((4-Ethyl-4-hydroxyhexyl)oxy)-9,10-secopregna-5,7,10(19)-triene-1alpha,3beta-diol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-[(4-ethyl-4-hydroxyhexyl)oxy]ethyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)-
(1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol | [Molecular Formula]
C29 H48 O4 | [MDL Number]
MFCD00867078 | [MOL File]
131875-08-6.mol | [Molecular Weight]
460.69 |
| Chemical Properties | Back Directory | [Boiling point ]
600.3±55.0 °C(Predicted) | [density ]
1.07±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C, protect from light, stored under nitrogen,unstable in solution, ready to use. | [solubility ]
DMSO | [form ]
Powder | [pka]
14.43±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Lexacalcitol is a 20-epi vitamin D3 analog with potent antitumor, calcemic, and immunosuppressive activity. | [in vivo]
Lexacalcitol (0.5 mg/kg/2 days; i.p.) in combination with cyclosporin A (CyA) can prevent autoimmune destruction of syngeneic islet grafts in spontaneously diabetic NOD recipients[2].
| Animal Model: | Male and female spontaneously diabetic NOD mice[2] | | Dosage: | 0.5 mg/kg/2 days | | Administration: | Intraperitoneal injection | | Result: | Single treatment with KH1060 or CyA did not result in statistically significant suppression of early graft failure, while the combination of KH1060 and CyA can prevent early graft failure and delay graft rejection of xenogeneic islets in spontaneously diabetic NOD mice. |
|
|
|